The Center of Personalized Medicine (ZPM) at TUM was founded to foster precision medicine across all areas of healthcare. The aim of the ZPM is to treat each patient optimally by integrating individual factors extensively, exceeding the functional diagnosis of the disease. Consequently, this also includes the constant tailoring of therapy to the progress of illness and recovery. The ZPM itself has been designed with a modular structure and the ZPM-Oncology serves as a template and use case for the foundation of other ZPMs with medical need in the area of precision medicine. Each ZPM displays an interdisciplinary structure and is organized around the seven core functions: molecular diagnostics, imaging, biobanking, individual therapy, data integration, training and education, and patient participation. At the ZPM-Oncology, patients with advanced malignant tumors for whom approved, or guideline-based therapies are not effective are offered advanced molecular diagnostic tests to find new and translational treatment options. The ZPM-Oncology TUM includes one of the largest Molecular Tumor Boards in Germany bringing together experts from different oncologic and research disciplines. It was the third German ZPM to be certified by the German Cancer Society (DKG) in 2023. The ZPM-Oncology TUM currently advises almost every second patient on a clinical trial and in 2 out of 3 cases recommends a personalized, translational therapeutic option. To extend the crucial precision medicine pioneering work in oncology to other fields with a high medical need and suitable molecular(-genetic) diagnostics, a stepwise expansion beyond the oncologic pilot in the field of inflammation, neurology and cardiology is next intended and based on structural measures.

Further, the Early Clinical Trial Unit (ECTU) of the TUM Hematology/Oncology Department plays a pivotal role in advancing precision medicine by tailoring medical treatments to the unique characteristics of each patient. Comprising a multidisciplinary team of experts, the ECTU conducts early-phase clinical trials that explore innovative therapies incorporating scientifically identified personalized treatment approaches and biomarker development. A prime example of successful integration and application of precision medicine in early clinical investigator-initiated trials at TUM is the COLPRIT trial (EudraCT 2015-001817-28). This prospective study investigates CXCR4-directed radioligand therapy (RLT) and aims to evaluate the efficacy, tolerable dosage, and side effects of [90Y]Pentixather RLT in patients with Multiple Myeloma and advanced Non-Hodgkin Lymphomas. Additionally, the SORATRAM trial (EudraCT 2016-003616-13), which investigates the use of Sorafenib and Trametinib in patients with advanced solid tumors harboring inactivating BRAF mutations, highlights the effective integration of molecular tumor boards (MTBs) and ECTUs within the framework of precision medicine.